Investors in Enliven Therapeutics Inc (Symbol: ELVN) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Enliven Therapeutics' stock rose after early trial results showed strong responses and good safety for its leukemia drug, ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

Investing.com -- Enliven Therapeutics (NASDAQ:ELVN) stock surged 7% Thursday after the biopharmaceutical company reported positive initial Phase 1b data for its chronic myeloid leukemia (CML) drug ...

Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...

Stocks are mixed as defense stocks surge, with the Dow Jones Industrial Average (DJI) up triple digits, while the Nasdaq Composite (IXIC) slides alongside tech ...

The company is juggling a lawsuit filed by the Round Table Owners Association and potential bankruptcy as franchisees demand ...

A Supreme Court ruling on tariffs and the U.S. jobs report were scheduled for Friday. ・Housing, biotech and aviation stocks ...

Major stock indexes finished mixed Thursday, with the blue-chip Dow Jones Industrial Average rising but the tech-heavy Nasdaq ...

Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...